Relationship between cardiopulmonary exercise testing parameters and heart failure risk (H2ARDD score) in atrial fibrillation  by Suzuki, Shinya et al.
Original Article
Relationship between cardiopulmonary exercise testing parameters
and heart failure risk (H2ARDD score) in atrial ﬁbrillation$
Shinya Suzuki, MDa,n, Akira Koike, MDb, Koichi Sagara, MDa, Takayuki Otsuka, MDa,
Hiroto Kano, MDa, Shunsuke Matsuno, MDa, Hideaki Takai, MDc, Tokuhisa Uejima, MDa,
Yuji Oikawa, MDa, Kazuyuki Nagashima, MDa, Hajime Kirigaya, MDa, Junji Yajima, MDa,
Hiroaki Tanabe, MDc, Hitoshi Sawada, MDa, Tadanori Aizawa, MDa, Takeshi Yamashita, MDa
a Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo 106 0031, Japan
b Faculty of Medicine, University of Tsukuba 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8575 Japan
c Department of Cardiovascular Surgery, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-Ku, Tokyo, Japan
a r t i c l e i n f o
Article history:
Received 12 September 2013
Accepted 19 September 2013
Available online 15 November 2013
Keywords:
Atrial ﬁbrillation
Heart failure
Cardiopulmonary exercise testing
a b s t r a c t
Background: A novel risk scoring system (H2ARDD) for estimating the incidence of heart failure (HF)
events in atrial ﬁbrillation (AF) has been developed, which represents points assigned for organic heart
disease (2 points), anemia (1 point), renal dysfunction (1 point), diabetes (1 point), and diuretic use
(1 point). We aimed to clarify whether H2ARDD score is related to cardiopulmonary exercise testing
(CPX) parameters in patients with AF.
Methods: The study population included 344 consecutive patients with AF who underwent CPX as initial
screening between June 2004 and March 2012. The association between 4 CPX parameters and the
incidence of HF events was analyzed by using multiple linear regression models.
Results: The peak O2 uptake (peak _VO2), anaerobic (gas exchange) threshold (AT), and ratio of the
increase in _VO2 to the increase in work rate (Δ _VO2/ΔWR) were lower and the slope of the increase in
ventilation to the increase in CO2 output ( _VE– _VCO2 slope) was higher in patients with than in those
without each H2ARDD score component. Accordingly, the parameters signiﬁcantly increased or
decreased according to H2ARDD score. With the multiple linear regression models, H2ARDD score was
independently associated with each CPX parameter even after adjustment for various cofactors.
Conclusions: H2ARDD score was independently associated with the well-established CPX parameters in
patients with AF, suggesting a potential pathophysiological basis for a risk stratiﬁcation system for
predicting HF events in patients with AF.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is the most common type of arrhythmia
in developed countries. Its prevalence almost doubles with each
decade of life [1], with a lifetime prevalence of 25% [2]. AF is also
an important risk factor for mortality [3].
Along with stroke, heart failure (HF), which is a signiﬁcant
complication of AF, was identiﬁed as an independent predictor of
mortality in patients with AF [4]. Our previous data suggested that
HF remains an important target for the treatment of AF to improve
patient prognosis [5]. To prevent hospital admission or death from
HF, identifying the population with a high-risk for such HF events
is mandatory. Therefore, we developed the H2ARDD scoring
system to measure the risk for HF events in patients with AF by
assigning points as follows: organic heart disease, 2 points;
anemia (hemoglobin levelo11 g/dL), 1 point; renal dysfunction
(estimated glomerular ﬁltration rate [GFR]o60 mL/min m2),
1 point; diabetes mellitus (DM), 1 point; and diuretic use, 1 point
[6]. Although it is a simple scoring system, it was a strong
predictor of the risk of HF events (hospital admission or death
from HF) in our AF patient population; the incidence rates of HF
events in patients scoring 0 and 6 points were 0.2% and 40.8% per
patient-year, respectively; C-statistic, 0.840 [6]. However, although
the clinical implications of the H2ARDD score were statistically
suggested, its pathophysiological basis has not been fully
evaluated.
Cardiopulmonary exercise testing (CPX) is the criterion stan-
dard for assessing exercise capacity, with much evidence for the
beneﬁts of its use in the clinical setting, especially for patients
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with systolic HF [7–14]. That evidence has also been extended to
patients with HF who have preserved left ventricular ejection
fraction [15–17]. The most important measurements obtained
from CPX include peak oxygen uptake (peak _VO2) [7,8,15,16],
anaerobic (gas exchange) threshold (AT) [9–11], increase rate in
ventilation per unit increase in carbon dioxide production
( _VE– _VCO2 slope) [12,13,17], and the ratio of the increase in _VO2
to the increase in work rate (Δ _VO2/ΔWR) [14], all of which reﬂect
heart disease severity and the ability of cardiac patients to perform
activities of daily living. In the present study, we evaluated
whether H2ARDD score is related to these 4 classic CPX para-
meters in patients with AF to clarify its pathophysiological
implications.
2. Materials and methods
2.1. Study patients
The Shinken Database (Shinken is the Japanese abbreviated
form of the name of the hospital) was established in June 2004 to
document new patients who visit the Cardiovascular Institute in
Tokyo, Japan. The principal aim of this hospital-based database is
to survey the prevalence and prognosis of cardiovascular diseases
in patients in an urban area of Japan [5,6]. Patients (except foreign
travelers and those with active cancer) have been registered
annually in the database since its inception.
Data from the Shinken Database recorded between June 2004
and March 2012 were used in the present study, including 17,517
newly admitted patients. From these patients, 344 consecutive
patients with AF who underwent CPX for evaluation of exercise
capacity and/or HF severity as initial screening at their initial visit
were extracted as the study population of the present study.
2.2. Data collection at initial visit
For each patient, an electrocardiogram (ECG), a chest radio-
graph, and laboratory data were obtained, and cardiovascular
status was evaluated by using echocardiography, CPX, and 24-h
Holter recordings within 3 months after the initial visit, according
to the discretion of the attending physician. Information regarding
each patient's medications was obtained from the hospital data-
base within 3 months after the initial visit [5,6].
2.3. Cardiopulmonary exercise testing
An incremental symptom-limited maximal exercise test was
performed by using an upright, electromagnetically braked cycle
ergometer (Corival 400, Lode BV, Groningen, the Netherlands).
After a 4-min warm-up at 0 or 20 W at 60 revolutions per minute
(rpm), the exercise load was increased incrementally by 1 W every
6 s (10 W/min). ECG was monitored continuously during the test
(ML-6500 or ML-9000 system, Fukuda Denshi Co., Ltd., Tokyo,
Japan). Cuff blood pressure was measured at rest on the cycle
ergometer and then every minute during exercise testing with an
automatic indirect manometer (STBP-780, Nippon Colin Co., Ltd.,
Aichi, Japan, or FB-300, Fukuda Denshi Co., Ltd.).
_VO2, _VCO2, and _VE were measured throughout the test with an
Aeromonitor AE-300S (Minato Medical Science, Osaka, Japan) [18].
Before the parameters from the respiratory gas analysis were
calculated, breath-by-breath data were interpolated to give
second-by-second values, which were then calculated as succes-
sive 3-s averages that were converted to a 5-point moving average.
Peak _VO2 was deﬁned as the average value obtained during the
last 15 s of incremental exercise. Δ _VO2/ΔWR was calculated from
the data recorded between 30 s after the start of incremental
exercise to 30 s before the end of the exercise, by using least
squares linear regression [14]. The _VE– _VCO2 slope was calculated
during incremental exercise by using least squares linear regres-
sion [14].
2.4. Deﬁnition of AF
In the present study, AF was diagnosed by using electrocardio-
graphic recordings, including 12-lead surface electrocardiograms
and 24-h Holter recordings performed within 3 months after the
initial visit, and based on the medical history of AF from the
patient's referring physicians. New-onset AF that occurred more
than 3 months after the initial visit was not included in the
diagnosis of AF in the present study.
2.5. H2ARDD score
The H2ARDD scoring system was developed for predicting the
risk for future incidence of HF events (admission or death by HF) in
patients with AF. The acronym H2ARDD represents organic heart
disease (2 points), anemia (hemoglobin levelo11 g/dL, 1 point),
renal dysfunction (estimated GFRo60 mg/min m2, 1 point), dia-
betes mellitus (hemoglobin A1c level [National Glycohemoglobin
Standardization Program]Z6.5%, or medical history of diabetes,
1 point), and diuretic use (1 point) [6]. For H2ARDD scoring, heart
disease includes one or more of the following: (1) valvular heart
disease with moderate or greater severity, left ventricular hyper-
trophy (intraventricular septal or posterior wall thicknessZ
14 mm), or left ventricular dysfunction (ejection fractiono50%)
on echocardiography; (2) previous diagnosis of coronary artery
disease based on coronary angiography ﬁndings; (3) previous
diagnosis of congenital heart disease; and (4) left ventricular
noncompaction on echocardiogram [6].
2.6. Ethical considerations
The ethics committee at the Cardiovascular Institute granted
permission for our database (2006/12/25, No. 95; 2011/4/8, No. 169),
and all patients provided written informed consent. The study was
performed in accordance with the Declaration of Helsinki.
2.7. Statistical analysis
Categorical and consecutive data pertaining to the patients'
background characteristics were presented as number (percen-
tage) and mean7standard deviation, respectively.
Differences in the distribution of CPX parameters according to
H2ARDD score and its components were ﬁrst identiﬁed. The
Student t test and one-way analysis of variance were used for
group comparisons of the CPX parameters between the presence
and absence of each H2ARDD score component and between the
H2ARDD score categories, respectively.
To evaluate the relationship between H2ARDD score with the
CPX parameters, simple and multiple linear regression analyses
were then performed. First, simple linear regression analysis was
performed by calculating the coefﬁcients of correlation between
the CPX parameters and various clinical variables, including
H2ARDD score, H2ARDD score components (organic heart disease,
anemia, renal dysfunction, diabetes mellitus, and diuretic use),
consecutive variables related to the H2ARDD score components
(B-type natriuretic peptide [BNP] level, left ventricular ejection
fraction [LVEF], hemoglobin level, estimated GFR, and hemoglobin
A1c level), and other clinical variables (sex, age, resting heart rate,
body mass index, body height, chronic AF, hypertension, and use
of β-blockers, renin–angiotensin system inhibitors, and statins).
Next, to evaluate the independent relationship between the
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H2ARDD score with the CPX parameters, the following 3 adjusted
multiple linear regression analysis models were performed:
H2ARDD scoreþcomponents of H2ARDD score (model 1), H2A-
RDD scoreþconsecutive variables related to components of H2AR-
DD score (model 2), and variables in model 2þother clinical
variables (model 3). Variables in each multivariate model were
selected in a forward stepwise method.
The analyses were performed by using SPSS version 19.0
software (SPSS Inc., Chicago, Illinois) for Windows (Microsoft
Corporation, Redmond, Washington). Statistical signiﬁcance was
set at 2-sided po0.05.
3. Results
3.1. Patient characteristics
The characteristics of the study patients (i.e., those with AF,
n¼344) are shown in Table 1. The patients with AF in the present
study included 266 men (77.3%) with a mean age of 62.7 years.
Organic heart disease and comorbidities of renal dysfunction,
diabetes mellitus, and anemia were observed in 167 (48.5%), and
in 103 (29.9%), 48 (14.0%), and 13 (3.8%) of the patients with AF,
respectively. β-Blockers, diuretics, anticoagulants, and antiplatelet
drugs were prescribed for 48.3%, 44.5%, 61.0%, and 54.7% of the
patients with AF, respectively.
3.2. Distribution of the CPX parameters according to H2ARRD score
The CPX parameters (peak _VO2, AT, _VE– _VCO2 slope, and Δ _VO2/
ΔWR) were worse in the patients with than in those without each
of the H2ARDD score components (Table 2). The only exception
was the association between _VE– _VCO2 slope and anemia, which
showed an insigniﬁcant difference (p¼0.243). Accordingly, as
these components accumulated, signiﬁcant differences were found
between low (0 point) and high (6 points) H2ARDD scores in peak
_VO2 (22.8 vs. 9.1 mL/min kg), AT (14.1 vs. 7.2 mL/min kg), _VE– _VCO2
slope (29.2 vs. 42.1), and Δ _VO2/ΔWR (10.3 vs. 6.5 mL/min W),
respectively (Fig. 1).
3.3. Relationship between CPX parameters and H2ARDD score
The coefﬁcients of correlation between the CPX parameters and
the various clinical variables are shown in Table 3. H2ARDD score
was signiﬁcantly associated with all the CPX parameters
(r¼0.568, 0.544, 0.457, and 0.474 for peak _VO2, AT, _VE– _V
CO2 slope, and Δ _VO2/ΔWR, respectively; all po0.001). Notably,
the consecutive variables related to the H2ARDD score compo-
nents (BNP level, LVEF, hemoglobin level, estimated GFR, and
hemoglobin A1c level) were all signiﬁcantly related to all of the
CPX parameters, with the exception of the hemoglobin A1c level
for peak _VO2, _VE– _VCO2 slope, and Δ _VO2/ΔWR.
Next, to identify the independent effects of the H2ARDD score
on the CPX parameters, the 3 adjusted multiple linear regression
analysis models were performed (Table 4). In model 1, the effects
of the H2ARDD score on the CPX parameters remained indepen-
dent after adjustment for the H2ARDD score components, with
attenuation of the effect of each component, suggesting that the
scoring system could work better for the accumulated parameters
than for the individual components. In model 2, the effects of the
H2ARDD score on the CPX parameters remained independent after
adjustment for consecutive variables related to the H2ARDD score
components. Moreover, in model 3, the effects of the H2ARDD
score on the CPX parameters remained independent even after
adjustment for other clinical variables, adding to the consecutive
variables in model 2.
4. Discussion
4.1. Major ﬁndings
We investigated the association between 4 CPX parameters
(peak _VO2, AT, _VE– _VCO2 slope, and Δ _VO2/ΔWR) and a novel scoring
system for the estimation of the risk for HF events in patients with
AF (the H2ARDD scoring system) and its components. Our ﬁndings
were as follows: (1) The CPX parameters were signiﬁcantly worse
Table 1
Background characteristics of the study patients with atrial ﬁbrillation.
Variable Total (n¼344)
Male sex 266 (77.3)
Age (years) 62.7710.6
Body mass index (kg/m2) 23.973.6
Paroxysmal atrial ﬁbrillation 136 (39.5)
Chronic atrial ﬁbrillation 208 (60.5)
Coexistence of organic heart disease 167 (48.5)
Valvular heart disease 124 (36.0)
Coronary heart disease 41 (11.9)
Myocardial infarction 17 (4.9)
Hypertrophic cardiomyopathy 6 (1.8)
Dilated cardiomyopathy 19 (5.5)
Others 0 (0.0)
New York Heart Association Class
I 225 (65.4)
II 84 (24.4)
III 28 (8.1)
IV 7 (2.0)
Z II 119 (34.6)
Comorbidities
Hypertension 138 (40.1)
Renal dysfunction 103 (29.9)
Dyslipidemia 88 (25.6)
Diabetes mellitus 48 (14.0)
Anemia 13 (3.8)
Cardiac indices and laboratory data
Resting heart rate (beats/min) 73.3717.8
Left ventricular ejection fraction (%) 58.1715.6
Brain natriuretic peptide (pg/mL) 258.37327.9
Hemoglobin (g/dL) 14.171.6
Estimated GFR (mL/min m2) 67.0715.7
Hemoglobin A1c (%) 6.070.8
H2ARDD score
0 111 (32.3)
1 50 (14.5)
2 40 (11.6)
3 67 (19.5)
4 63 (18.3)
5 11 (3.2)
6 2 (0.6)
Medications
β-Blockers 166 (48.3)
Renin–angiotensin system inhibitors 152 (44.2)
Angiotensin-converting enzyme inhibitors 52 (15.1)
Angiotensin II receptor blockers 122 (35.5)
Diuretics 153 (44.5)
Loop diuretics 145 (42.2)
Thiazides 21 (6.1)
Potassium-sparing diuretics 117 (34.0)
Antiarrhythmic drug other than β-blockers
Class I antiarrhythmic drug 53 (15.4)
Class III antiarrhythmic drug 19 (5.5)
Class IV antiarrhythmic drug 62 (18.0)
Digitalis 86 (25.0)
Antithrombotic drugs
Anticoagulants 210 (61.0)
Antiplatelet drugs 188 (54.7)
Categorical and consecutive data are presented as number (percentage) and
mean7standard deviation, respectively.
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in the patients with than in those without each of H2ARDD score
compared with those without them. (2) Accordingly, the CPX
parameters were signiﬁcantly different between the low and high
H2ARDD scores, which seemed to reﬂect the cumulative effect of
each H2ARDD score component. Finally, (3) the H2ARDD score was
independently associated with all the 4 CPX parameters even after
adjustment for various clinical covariates.
4.2. Clinical implications
HF is a complication of AF that signiﬁcantly affects the patients'
mortality [4]. The incidence rate of HF in patients with AF has been
reported to be approximately 1–10% per year [4,6,19–21], although
the ﬁgure is widely distributed according to patient backgrounds.
The ﬁrst, crucial step in preventing the development of HF in
Table 2
Differences in cardiopulmonary exercise testing parameters according to each H2ARDD score component.
H2ARDD score components Peak _VO2 (mL/min kg) AT (mL/min kg) _VE– _VCO2 slope Δ _VO2/ΔWR (mL/min W)
Organic heart disease
Yes (n¼167) 16.075.3 10.772.9 36.078.7 8.572.0
No (n¼177) 21.675.8 13.573.0 30.275.8 10.071.8
p Value o0.001 o0.001 o0.001 o0.001
Anemia
Yes (n¼13) 13.475.1 9.672.9 35.577.1 7.371.6
No (n¼331) 19.176.2 12.273.2 32.977.9 9.472.0
p Value 0.001 0.004 0.243 o0.001
Renal dysfunction
Yes (n¼103) 16.175.8 10.773.1 36.479.5 8.472.1
No (n¼241) 20.176.0 12.773.1 31.676.6 9.771.8
p Value o0.001 o0.001 o0.001 o0.001
Diabetes mellitus
Yes (n¼48) 15.674.7 10.772.7 35.378.4 8.772.2
No (n¼296) 19.476.3 12.373.2 32.777.7 9.471.9
p Value o0.001 o0.001 0.033 0.027
Diuretics use
Yes (n¼153) 15.475.3 10.472.9 36.678.8 8.372.1
No (n¼191) 21.675.5 13.572.8 30.275.6 10.071.6
p Value o0.001 o0.001 o0.001 o0.001
The parameter data are presented as mean7standard deviation.
Fig. 1. Cardiopulmonary exercise testing parameters in the AF patients according to H2ARDD score.
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patients with AF is to identify high-risk patients. We therefore
previously focused on the risk of hospitalization or death from HF,
without distinguishing histories of HF, and developed a novel risk-
scoring system, the H2ARDD scoring system [6].
CPX is a recognized modality for assessing exercise capacity.
Classic CPX parameters, including peak _VO2, AT, _VE– _VCO2 slope,
and Δ _VO2/ΔWR, all reﬂect heart disease severity and the ability
of cardiac patients to perform activities of daily living [7–17].
The peak _VO2 in cardiac patients generally reﬂects maximal
cardiac output, or the pumping reserve of the heart. The _VE– _V
CO2 slope, which ranges from approximately 24–34 in healthy
subjects, becomes steeper in cardiac patients according to heart
failure severity [22]. Theoretically, a steep _VE– _VCO2 slope during
exercise is assumed to relate to ventilation/perfusion mismatch
such as an increased ratio of pulmonary dead space to tidal
volume. Lactic acidosis from exercise occurs at lower intensities
as heart disease worsens, which is reﬂected by a lower AT. Δ _VO2/
ΔWR reﬂects the rate of increase in cardiac output during incre-
mental exercise [23] and decreases with heart disease severity.
In the present study, we evaluated whether H2ARDD score is
related to the 4 classic CPX parameters to clarify the pathophy-
siological basis of the risk-scoring system and found that the
H2ARDD score was signiﬁcantly associated with all of the CPX
parameters. Moreover, the association is independent even after
adjustment for various clinical covariates. These results provide a
potential pathophysiological basis for the H2ARDD score as a risk-
scoring system for predicting HF events in patients with AF.
4.3. Pathophysiological link between the H2ARDD score components
and the CPX parameters
Here we discuss why H2ARDD score might be related to the
CPX parameters. Oxygen uptake increases during incremental
exercise, with peak _VO2 representing the highest rate of oxygen
uptake achieved. A reduction in its level may result from a variety
of factors [24], including limited cardiac output, poor peripheral
blood ﬂow, impaired skeletal muscle metabolism, or early termi-
nation of the test because of cardiac-related or other symptoms.
A similar relationship existed between the H2ARDD score in our
study and AT because AT and peak _VO2 were similarly affected by
HF severity or the patients' backgrounds, including age [10].
In patients with organic heart disease, limited cardiac output,
either from reduced systolic [13] or impaired diastolic function
[16], is the main cause of reductions in peak _VO2, AT, and Δ _VO2/
ΔWR and an increase in _VE– _VCO2 slope.
Patients with diabetes mellitus, either type 1 or 2, exhibit
exercise intolerance [25,26]. This may be explained in part by
myocardial contractile dysfunction resulting from exposure to
high blood glucose levels via mitochondrial dysfunction or extra-
cellular matrix remodeling, linking to advanced glycation end
products (AGEs) [27]. The exercise intolerance seen in patients
with DM may also be explained by systemic problems, including
impaired bioenergetic capacity of skeletal muscle mitochondria
[28], impaired capillary recruitment in exercising muscles [29], or
impaired chronotropic response to exercise.
The role of anemia in exercise intolerance can be understood
simply as reduced oxygen delivery to the exercising muscles.
Anemia is more prevalent in severe HF and is known to worsen
patient prognosis in HF [30]. The potential mechanisms by which
anemia can worsen HF include exacerbation of myocardial and
peripheral hypoxia, increased venous return and cardiac work, and
consequent left ventricular hypertrophy. Hypoxia can also poten-
tially lead to activation of neurohormones and cytokines. In turn,
cytokines can exacerbate the anemia, leading to a vicious cycle, the
so-called cardiorenal anemia syndrome [31]. Peak _VO2 and exer-
cise duration were reported to be signiﬁcantly improved by
Table 3
Coefﬁcient of correlation between the cardiopulmonary exercise testing parameters and various clinical variables.
Variables Peak _VO2 AT _VE– _VCO2 slope Δ _VO2/ΔWR
H2ARDD score 0.568nnn 0.544nnn 0.457nnn 0.474nnn
Components of H2ARDD score
Organic heart disease 0.452nnn 0.433nnn 0.373nnn 0.356nnn
Anemia 0.173nn 0.155nn 0.063 0.199nnn
Renal dysfunction 0.294nnn 0.287nnn 0.282nnn 0.302nnn
Diabetes mellitus 0.214nnn 0.181nnn 0.115n 0.120n
Diuretic use 0.495nnn 0.486nnn 0.407nnn 0.424nnn
Consecutive variables related to components of H2ARDD score
Brain natriuretic peptide (pg/mL) 0.357nnn 0.347nnn 0.424nnn 0.332nnn
Left ventricular ejection fraction (%) 0.216nnn 0.250nnn 0.190nnn 0.200nnn
Hemoglobin (g/dL) 0.358nnn 0.305nnn 0.225nnn 0.379nnn
Estimated GFR (mL/min m2) 0.293nnn 0.270nnn 0.265nnn 0.310nnn
Hemoglobin A1c (%) 0.130 0.150n 0.104 0.028
Other clinical variables
Male sex 0.277nnn 0.221nnn 0.107n 0.286nnn
Age (years) 0.429nnn 0.271nnn 0.302nnn 0.292nnn
Resting heart rate (beats/min) 0.214nnn 0.214nnn 0.124n 0.223nnn
Body mass index (kg/m2) 0.038 0.035 0.172nn 0.272nnn
Body height (cm) 0.342nnn 0.241nnn 0.196nnn 0.346nnn
Chronic form of atrial ﬁbrillation 0.064 0.017 0.141nn 0.076
Hypertension 0.181nnn 0.120n 0.052 0.101
β-Blocker use 0.291nnn 0.325nnn 0.173nn 0.311nnn
Renin–angiotensin system inhibitor use 0.458nnn 0.442nnn 0.239nnn 0.345nnn
Statin use 0.230nnn 0.220nnn 0.086 0.086
Peak _VO2, peak O2 uptake; AT, anaerobic (gas exchange) threshold; _VE– _VCO2 slope, slope of the increase in ventilation to the increase in CO2 output;
Δ _VO2/ΔWR, ratio of the increase in _VO2 to the increase in work rate.
nnn po0.001.
nn po0.01.
n po0.05.
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normalization of hemoglobin concentration by erythropoietin
administration in patients with HF [32], demonstrating the sig-
niﬁcant role of hemoglobin concentration in exercise capacity.
However, the role of renal dysfunction in exercise intolerance is
less easily understood. One possible explanation is an indirect link
via the coexistence of atherosclerotic disease. Factors associated
with renal dysfunction, including oxidative stress, inﬂammation,
and conditions promoting coagulation, are known to promote
atherosclerosis and impair endothelial function [33]. Thus, renal
dysfunction is strongly associated with ischemic heart disease
[34]. Renal dysfunction can also be exacerbated by reduced renal
perfusion as a consequence of left ventricular dysfunction.
Diuretic use indicates that a patient is in a state of diuretic-
dependent HF and, as such, is merely a marker for a particular HF
state. However, it is independently statistically associated with all
the 4 classic CPX parameters in the present study.
4.4. Study limitations
CPX was performed for patients with particular indications for
evaluating exercise capacity and/or HF severity. Thus, the subjects
in the present study may not represent the general AF patient
population. In addition, our database consisted of a cohort of
patients from a single cardiovascular hospital in Japan, and the
study population included only Japanese patients. Therefore, the
results should be carefully interpreted when applied to different
populations.
5. Conclusions
In this study, the H2ARDD score was independently associated
with the well-established CPX parameters in our patients with AF.
This result provides a potential pathophysiological basis for the
H2ARDD scoring system as a method of risk stratiﬁcation to
predict HF events in patients with AF.
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